Update 17 July, 2024, 3:14 p.m. ET: Cassava Sciences CEO and SVP of neuroscience have resigned from the company following news of federal probes….
How does science go from the lab to the news stand? Scientists design experiments to test an idea or hypothesis. Some experiments involve lots…
It’s an exciting time for Alzheimer’s research, according to Madhav Thambisetty, senior investigator at the National Institute on Aging. “We’ve known for years that…
The monoclonal antibody drugs targeting the brain’s amyloid plaques dominated the news cycle in 2023. Eisai and Biogen’s Leqembi was approved by the FDA…
Biogen and Eisai’s monoclonal antibody drugs for Alzheimer’s — Aduhelm (now off the market) and Leqembi (fully approved by the FDA in 2023) —…
Experts estimate that, by 2023, nearly 40 percent of the more than eight million Americans living with Alzheimer’s and related dementias will be Latino…
About 14 of every 100 of Black Americans older than 65 have Alzheimer’s disease, compared 10 in 100 white Americans of the same age…
The process of finding new treatments for Alzheimer’s disease is one of trial and error — and every “failed” trial generates invaluable new data…
There are dozens of new approaches to treating Alzheimer’s currently in clinical trials. But while some promising innovations in diagnostics and intervention are progressing…
Alzheimer’s disease affects one in every three people over the age of 85, and the scale of the epidemic is only worsening. While there…
Over 55 million people worldwide have dementia. This mind-robbing condition has a huge impact on society and the economy, so scientists are working hard…
Have you heard of Wegovy, Ozempic, and Mounjaro? These new medications — that muffle hunger signals in the brain — are all the rage….
As Dr. Jeff Chen MD, MBA recalled in a recent talk at the 2023 TED Conference in Vancouver, BC, when he was a medical…
Since the United States imposed an embargo on Cuba in 1961, the island nation has built a robust healthcare system on their own, with…
After almost two decades of stagnation, two new drugs for Alzheimer’s have hit the market in the last three years. The approval of Biogen…